Galena Biopharma Inc (NASDAQ:GALE) said it has dosed the first patient in a new NeuVax Phase 2 clinical trial to prevent breast cancer recurrence in high risk HER2 3+ and/or HER2 gene-amplified breast cancer patients in combination with Herceptin. The multi-center, prospective, randomized, single-blinded, placebo-controlled, Phase 2 trial will enroll 100 patients with a diagnosis of HER2 3+ or gene-amplified breast cancer, are HLA A2+ or HLA A3+, and are determined to be at high-risk for recurrence. "This trial is a significant addition to our portfolio of NeuVax clinical trials that are exploring the potential of the agent to prevent recurrence in a variety of cancer settings," said Mark W. Schwartz, Ph.D., President and Chief Executive Officer. Galena Biopharma Inc (NASDAQ:GALE) shares closed at $1.93 on Monday with a 52-week range of $1.56 - $7.77.Click here for a free comprehensive Trend Analysis ReportQiwi PLC (NASDAQ:QIWI), a payment services provider in Russia and the CIS, announced Q3 results that beat the Street view on both EPS and total revenue and has increased full year guidance. The company reported Q3 adjusted EPS of RUB28.39 ($0.72), up from RUB10.27 in Q3 2013 and beating analyst estimates of $0.36 for the quarter. Total revenues of RUB3.82 billion ($97.04 million) were up from RUB2.97 billion in Q3 2013 and topped analyst projections of $50.50 million. Payment adjusted net revenue growth was predominantly driven by an increase in payment volume and net revenue yield in the E-commerce, Financial Services and Money Remittances market segments.Qiwi PLC (NASDAQ:QIWI) has raised its 2014 outlook, with total adjusted net revenue now expected to increase by 32% to 40% over 2013, up from previous guidance of 30 to 32%, and adjusted net profit expected to increase by 60% to 70% over 2013, up from previous guidance of 36% to 38%. The company's Board of Directors has recommended a dividend of $0.38 per share, down from $0.46 in the previous quarter, payable November 26 to shareholders of record on November 24. Shares of QIWI are trading within a 52-week range of $26.14 - $59.24.Click here for a free comprehensive Trend Analysis ReportPDL BioPharma Inc (NASDAQ:PDLI), the biotech company reported Q3 revenue trailing analyst expectations. Net income rose to $102.2 million, or $0.61 per share, up from a $56.2 million profit last year and beating the Street view by $0.06 per share. Total revenue during the three months ended Sept 30 rose 64% year over year to $164.6 million, lagging the Capital IQ consensus by around $500,000. PDL BioPharma Inc (NASDAQ:PDLI) also said it will provide its outlook for fiscal Q4 results next month, adhering to company policy for releasing financial guidance during the third month of each quarter.Click here for a free comprehensive Trend Analysis Report
Discover Hidden Gems
Don't miss the next big opportunity. Subscribe for timely alerts on potential market movers.
